ArriVent BioPharma

AVBP · NASDAQ

$18.85+$0.91 (+5.07%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $17.94

AVBP analyst rating

BuyConsensus of 12 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy12
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $45.81 (+143.0% upside)

Low: $40.40
Now: $18.85
High: $52.50

Upgrades and downgrades

The latest rating actions, newest first

AVBP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Oct 20, 2026	Maintains	Buy	$45.00 → $29.00	37%
BTIG	Oct 16, 2026	Maintains	Buy	$29.00	54%
HC Wainwright & Co.	Oct 8, 2026	Maintains	Buy	$47.00 → $27.00	41%
Citigroup	Oct 7, 2026	Maintains	Buy	$40.00 → $20.00	42%
Jones Trading	Oct 7, 2026	Maintains	Buy	$45.00 → $22.00	31%
Truist Securities	Oct 7, 2026	Maintains	Buy	$45.00 → $18.00	25%
Guggenheim	Oct 7, 2026	Maintains	Buy	$45.00 → $18.00	62%
BTIG	Oct 7, 2026	Maintains	Buy	$42.00 → $29.00	54%
HC Wainwright & Co.	Aug 17, 2026	Maintains	Buy	$44.00 → $47.00	41%
Citigroup	Aug 13, 2026	Maintains	Buy	$43.00 → $40.00	42%

The case for and against

Updated Oct 14, 2026

Bull case

ArriVent BioPharma is supported by a diversified oncology pipeline that still offers multiple shots on goal despite FURVENT missing its Phase 3 PFS endpoint, as firmonertinib showed an 11.0-month mPFS by BICR versus 9.5 months for control and 60% versus 33% cORR, while overall survival trends remain positive. Its balance sheet is another key strength, with $373M of cash as of 2Q26 providing runway into 2028, reducing near-term financing risk and allowing continued investment in development. The highest-conviction catalyst is ARR-217 at ESMO, where ~20% ORR across doses and ~25% at potential go-forward doses in mCRC could meaningfully re-rate the stock, especially given the >$18Bn U.S. CDH17 opportunity and the ongoing ALPACCA Phase 3 trial.

Bear case

ArriVent BioPharma is viewed negatively because its valuation depends heavily on clinical-stage assets that have yet to prove themselves in humans, leaving the investment case vulnerable to readout risk, regulatory uncertainty, and competition. ARR-217 only entered Phase 1 clinical development in mid-2025, with initial clinical data not expected until 1H27, so the pipeline offers limited near-term visibility and may be judged against stronger benchmark data such as AMT-676’s 26% ORR and notable G3+ TRAEs. The company also faces slower-than-expected ALPACCA enrollment, negative efficacy data, and medium-term equity dilution risk, while the stated 49.7 million shares outstanding as of end-2026 underscores potential financing pressure.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.